Loading stock data…
Anixa Biosciences, Inc. (ANIX)
$2.79+0.17 (+6.49%)
Market ClosedLast close Jun 26
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Anixa Biosciences, Inc. in the Healthcare sector is trading at $2.79 with a market capitalization of $84M. Wall Street consensus targets $10.00 (3 analysts), implying a +258.4% move over the next 12 months. The stock is currently near its 52-week low of $2.32, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +258.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.72M↑ | -$2.88M↓ | -$2.44M↑ | -$3.00M↑ | -$3.39M |
| Net Income | -$2.56M↑ | -$2.69M↓ | -$2.26M↑ | -$2.79M↑ | -$3.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T ce...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.37%
Volume
Today's trading volume
1.04M
Recent News
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference
Anixa Biosciences (NASDAQ:ANIX) CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what he described as a “very modest” cash burn during a Water Tower Research conference session moderated by Robert Sassoon, Managing Director of He
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress
Anixa Biosciences (NASDAQ:ANIX) held its 2026 Annual Meeting of Stockholders via live webcast, outlining the results of shareholder votes and providing an operational update focused on the company’s clinical-stage oncology pipeline and partnership-driven strategy. Annual meeting votes and quorum Pr
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance
Anixa Biosciences (NASDAQ:ANIX) Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a breast cancer vaccine being developed with the Cleveland Clinic and the U.S. Department of Defense, and a CAR-T cell therapy for terminally il
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...